Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia
Biosimilars are safe and effective treatments for chronic diseases such as cancer and rheumatoid arthritis. The Saudi Food and Drug Authority (SFDA) manages the quality and registration of biosimilars in the Kingdom of Saudi Arabia. However, disparities among regulatory authorities, such as the abse...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University of Minnesota Libraries Publishing
2024-11-01
|
| Series: | INNOVATIONS in Pharmacy |
| Subjects: | |
| Online Access: | https://pubs.lib.umn.edu/index.php/innovations/article/view/6371 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861361177788416 |
|---|---|
| author | Mohammed Alqahtani Ahmed Al-jedai Albert Wertheimer |
| author_facet | Mohammed Alqahtani Ahmed Al-jedai Albert Wertheimer |
| author_sort | Mohammed Alqahtani |
| collection | DOAJ |
| description | Biosimilars are safe and effective treatments for chronic diseases such as cancer and rheumatoid arthritis. The Saudi Food and Drug Authority (SFDA) manages the quality and registration of biosimilars in the Kingdom of Saudi Arabia. However, disparities among regulatory authorities, such as the absence of guidelines for biosimilars for rheumatologists, impact healthcare providers' perceptions, leading to hesitation in switching from reference products to biosimilars. The study aimed to predict Saudi healthcare professionals’ intentions toward biosimilars. Methods: A convenience sample of 87 participants (75 pharmacists and 12 physicians) was analyzed. The data were collected between December 2022 and February 2023. A logistic regression model was used to predict the intention toward biosimilars. Result: Years of practice among physicians significantly influenced their intention to prescribe biosimilars. Positive correlations were also observed between intentions towards prescription and beliefs regarding the safety and efficacy of biosimilars. Pharmacists' authority and knowledge of biosimilars correlated with their intention to substitute or dispense them. However, the logistic regression analysis indicated that behavioral, normative, and control beliefs were not significant predictors of the intention to prescribe or substitute biosimilars in either group. Conclusion: Highlighting the significance of continuing education and coordinating efforts in the international harmonization of biosimilar guidelines, as well as education for healthcare professionals, is required for addressing clinical concerns and enhancing confidence in biosimilars.
|
| format | Article |
| id | doaj-art-af6d5b3fe8d5497c9188305c6d97293e |
| institution | Kabale University |
| issn | 2155-0417 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | University of Minnesota Libraries Publishing |
| record_format | Article |
| series | INNOVATIONS in Pharmacy |
| spelling | doaj-art-af6d5b3fe8d5497c9188305c6d97293e2025-02-09T21:38:42ZengUniversity of Minnesota Libraries PublishingINNOVATIONS in Pharmacy2155-04172024-11-0115410.24926/iip.v15i4.6371Perceptions of Biosimilars Among Healthcare Providers in Saudi ArabiaMohammed AlqahtaniAhmed Al-jedai0Albert Wertheimer1Ahmed Al-jedai, Assistant Deputy Minister for Medical support Services| Deputyship of Therapeutic Affairs| Ministry of Health, Riyadh, Saudi Arabia| Professor, Alfaisal University, Colleges of Medicine and Pharmacy| Consultant Clinical Pharmacist, Solid Organ Transplant|College of Pharmacy, Department of Sociobehavioral and Administrative Pharmacy, Nova Southeastern University, USA.Biosimilars are safe and effective treatments for chronic diseases such as cancer and rheumatoid arthritis. The Saudi Food and Drug Authority (SFDA) manages the quality and registration of biosimilars in the Kingdom of Saudi Arabia. However, disparities among regulatory authorities, such as the absence of guidelines for biosimilars for rheumatologists, impact healthcare providers' perceptions, leading to hesitation in switching from reference products to biosimilars. The study aimed to predict Saudi healthcare professionals’ intentions toward biosimilars. Methods: A convenience sample of 87 participants (75 pharmacists and 12 physicians) was analyzed. The data were collected between December 2022 and February 2023. A logistic regression model was used to predict the intention toward biosimilars. Result: Years of practice among physicians significantly influenced their intention to prescribe biosimilars. Positive correlations were also observed between intentions towards prescription and beliefs regarding the safety and efficacy of biosimilars. Pharmacists' authority and knowledge of biosimilars correlated with their intention to substitute or dispense them. However, the logistic regression analysis indicated that behavioral, normative, and control beliefs were not significant predictors of the intention to prescribe or substitute biosimilars in either group. Conclusion: Highlighting the significance of continuing education and coordinating efforts in the international harmonization of biosimilar guidelines, as well as education for healthcare professionals, is required for addressing clinical concerns and enhancing confidence in biosimilars. https://pubs.lib.umn.edu/index.php/innovations/article/view/6371Biosimilarsintentionperceptionsinterchangeability |
| spellingShingle | Mohammed Alqahtani Ahmed Al-jedai Albert Wertheimer Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia INNOVATIONS in Pharmacy Biosimilars intention perceptions interchangeability |
| title | Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia |
| title_full | Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia |
| title_fullStr | Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia |
| title_full_unstemmed | Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia |
| title_short | Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia |
| title_sort | perceptions of biosimilars among healthcare providers in saudi arabia |
| topic | Biosimilars intention perceptions interchangeability |
| url | https://pubs.lib.umn.edu/index.php/innovations/article/view/6371 |
| work_keys_str_mv | AT mohammedalqahtani perceptionsofbiosimilarsamonghealthcareprovidersinsaudiarabia AT ahmedaljedai perceptionsofbiosimilarsamonghealthcareprovidersinsaudiarabia AT albertwertheimer perceptionsofbiosimilarsamonghealthcareprovidersinsaudiarabia |